Aspartic acid

Generic Name: Aspartic acid

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₄H_₇NO_₄

CAS Number: 56-84-8

Unique Ingredient Identifier: 30KYC7MIAI

Background: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Indication: There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

Associated Therapies: Amino acid supplementation

Clinical Trials

Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy

Not Applicable

Completed

Conditions: Vitamin D Deficiency
Chemotherapy Effect
Pathology

Interventions: Drug: Vit D

First Posted Date: 2019-06-14

Last Posted Date: 2024-02-22

Lead Sponsor: Florence Nightingale Hospital, Istanbul

Target Recruit Count: 64

Registration Number: NCT03986268

Locations: 🇹🇷
İstanbul Florence Nightingale Hospital Breast Health Center, Istanbul, Şişli, Turkey

Vitamin D and Hereditary Haemorrhagic Telangiectasia

Phase 2

Conditions: Hereditary Haemorrhagic Telangiectasia

Interventions: Drug: Vit D
Drug: Placebo Oral Tablet

First Posted Date: 2019-06-11

Last Posted Date: 2019-06-11

Lead Sponsor: St. Paul's Hospital, Canada

Target Recruit Count: 60

Registration Number: NCT03981562

Locations: 🇨🇦
E.N.T Clinic, St. Paul's Hospital, Vancouver, British Columbia, Canada

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G
Drug: Treatment H

First Posted Date: 2019-06-06

Last Posted Date: 2019-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT03978143

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment D
Drug: Treatment F
Drug: Treatment C
Drug: Treatment E

First Posted Date: 2019-05-08

Last Posted Date: 2020-07-22

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 30

Registration Number: NCT03942666

Locations: 🇧🇪
SGS Life Sciences - Clinical Pharmacology Unit Antwerpen, Antwerp, Belgium

Omega-3 and Vitamin D Supplements in Childhood T1D

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: omega-3 supplementation
Drug: Vitamin D supplementation

First Posted Date: 2019-04-11

Last Posted Date: 2021-04-19

Lead Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita

Target Recruit Count: 64

Registration Number: NCT03911843

Combined Oral Vitamin D and UVB Versus UVB Alone in Treatment of Psoriasis Vulgaris

Early Phase 1

Conditions: Psoriasis Vulgaris

First Posted Date: 2019-03-14

Last Posted Date: 2019-03-14

Lead Sponsor: Assiut University

Target Recruit Count: 40

Registration Number: NCT03874975

A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D

First Posted Date: 2019-01-15

Last Posted Date: 2021-04-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 12

Registration Number: NCT03804645

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

Early Phase 1

Completed

Conditions: Gastric Retention
Healthy

Interventions: Drug: Formulation A
Drug: Formulation B
Drug: Formulation C
Drug: Formulation D
Drug: Formulation E
Procedure: Magnetic Resonance Imaging
Procedure: Endoscopy

First Posted Date: 2018-10-24

Last Posted Date: 2019-02-26

Lead Sponsor: Lyndra Inc.

Target Recruit Count: 40

Registration Number: NCT03718390

Locations: 🇦🇺
CMAX, Adelaide, South Australia, Australia

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

Phase 1

Completed

Conditions: Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)
Healthy Participants

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D
Drug: Acetaminophen

First Posted Date: 2018-08-28

Last Posted Date: 2018-11-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT03649165

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Treatment A
Drug: Treatment D
Drug: Treatment B
Drug: Treatment E
Drug: Treatment C
Drug: Treatment F

First Posted Date: 2018-02-22

Last Posted Date: 2019-12-09

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 36

Registration Number: NCT03441984

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy